NR1H4 nuclear receptor binding compounds

US6974830B2 · kind B2 · utility

Assignee

• PHENEX PHARMACEUTICALS AG · DE

Inventors

• Ulrike Bauer · Sandhausen, DE
• Zach Cheruvallath · San Diego, US
• Ulrich Deuschle · Bammental, DE
• Elena Dneprovskaia · San Diego, US
• Tim Gahman · Encinitas, US
• Kristina Giegrich · Lampertheim, DE
• Ronnie Hanecak · San Clemente, US
• Normand Hebert · Irvine, US
• John S. Kiely · San Diego, US
• Ingo Kober · Groß-Gerau, DE
• Manfred Kögl · Eppelheim, DE
• Harald Kranz · Leimen, DE
• Claus Kremoser · Heidelberg, DE
• Matthew Lee · Calabasas, US
• Kerstin Otte · Heidelberg, DE
• Carlton Sage · Irvine, US
• Manish Sud · San Diego, US

Key dates

• Filing date: Jul 1, 2002
• Grant date: Dec 13, 2005
• Expiry date: Jul 1, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/11
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds according to the general formula (I) which bind to the NR1H4 receptor and act as agonists of the NR1H4 receptor. The invention further relates to the treatment of diseases and/or conditions through binding of the nuclear receptor by the compounds and the production of medicaments using the compounds.